Online citations, reference lists, and bibliographies.
← Back to Search

Randomized Phase III Trial Of Capecitabine Compared With Bevacizumab Plus Capecitabine In Patients With Previously Treated Metastatic Breast Cancer.

K. Miller, L. Chap, F. Holmes, M. Cobleigh, P. Marcom, L. Fehrenbacher, M. Dickler, B. Overmoyer, J. D. Reimann, A. Sing, V. Langmuir, H. Rugo
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PURPOSE This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. PATIENTS AND METHODS Patients were randomly assigned to receive capecitabine (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks, alone or in combination with bevacizumab (15 mg/kg) on day 1. The primary end point was progression-free survival (PFS), as determined by an independent review facility. RESULTS From November 2000 to March 2002, 462 patients were enrolled. Treatment arms were balanced. No significant differences were found in the incidence of diarrhea, hand-foot syndrome, thromboembolic events, or serious bleeding episodes between treatment groups. Of other grade 3 or 4 adverse events, only hypertension requiring treatment (17.9% v 0.5%) was more frequent in patients receiving bevacizumab. Combination therapy significantly increased the response rates (19.8% v 9.1%; P = .001); however, this did not result in a longer PFS (4.86 v 4.17 months; hazard ratio = 0.98). Overall survival (15.1 v 14.5 months) and time to deterioration in quality of life as measured by the Functional Assessment Of Cancer Treatment--Breast were comparable in both treatment groups. CONCLUSION Bevacizumab was well tolerated in this heavily pretreated patient population. Although the addition of bevacizumab to capecitabine produced a significant increase in response rates, this did not translate into improved PFS or overall survival.
This paper references
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes
M. Relf (1997)
10.1093/ANNONC/MDG346
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
P. Reichardt (2003)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.1200/JCO.2001.19.3.843
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
M. Gordon (2001)
10.1093/JNCI/89.14.1044
Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients.
S. Fox (1997)
10.1093/JNCI/82.1.4
What is the evidence that tumors are angiogenesis dependent?
J. Folkman (1990)
10.1053/J.SEMINONCOL.2003.08.013
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.
M. Cobleigh (2003)
10.1056/NEJM199101033240101
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
N. Weidner (1991)
10.1056/NEJM199810013391407
Treatment of breast cancer.
G. Hortobagyi (1998)
10.1210/EDRV.18.1.0287
The biology of vascular endothelial growth factor.
N. Ferrara (1997)
10.1126/SCIENCE.6181563
Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer.
H. Jensen (1982)
10.1038/362841A0
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
K. J. Kim (1993)
10.1200/JCO.1996.14.8.2197
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
P. A. Greenberg (1996)
The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients.
S. Hansen (2000)
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis.
D. Weinstat-Saslow (1994)
10.1016/S0002-9440(10)65713-6
Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor.
S. W. Mcleskey (1998)
10.1016/S0140-6736(95)92345-4
Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery
P. Mcculloch (1995)
10.1093/JNCI/84.24.1875
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.
N. Weidner (1992)
10.1053/AJKD.2002.32797
Nephrotic syndrome after treatment with pamidronate.
G. Markowitz (2002)
10.1200/JCO.1997.15.3.974
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
M. Brady (1997)
Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
G. Markowitz (2001)
10.1126/SCIENCE.402692
Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia.
S. Brem (1977)
10.3322/canjclin.53.1.5
Cancer Statistics, 2003
A. Jemal (2003)
10.1200/JCO.1999.17.2.485
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
J. Blum (1999)



This paper is referenced by
10.17265/2328-2150/2017.03.007
Pseudocirrhosis after the Use of Taxanes and Bevacizumab in Metastatic Breast Cancer: Case Reports
Gabriel Lima Lopes (2017)
10.1093/eurheartj/ehn384
Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?
D. Pereg (2008)
10.2165/00024669-200605020-00004
First-Line Treatment of Metastatic Breast Cancer
F. Puglisi (2006)
10.1097/01.cco.0000397417.75245.9c
Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer
M. Damasceno (2011)
10.1111/j.1365-2354.2012.01370.x
Quality of life assessments in advanced breast cancer: should there be more consistency?
E. Reed (2012)
10.5493/wjem.v5.i3.194
Eribulin for heavily pre-treated metastatic breast cancer patients.
A. Digklia (2015)
10.1016/j.ejso.2009.01.014
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
R. Greil (2009)
10.1177/1758834010397627
Bevacizumab in metastatic breast cancer: when may it be used?
S. Goldfarb (2011)
10.3322/caac.20075
Angiogenesis Inhibitors: Current Strategies and Future Prospects
K. Cook (2010)
10.1038/sj.bjc.6605663
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
J. Feliu (2010)
10.2146/ajhp080088
Treatment-experienced breast cancer.
L. Michaud (2008)
10.1159/000260904
First-Line Capecitabine Monotherapy for Slowly Progressing Metastatic Breast Cancer: Do We Need Aggressive Treatment?
M. Debled (2009)
10.1186/s12882-018-1074-3
Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
Yoshitaka Furuto (2018)
10.1007/978-1-59745-337-0_24
VEGF Inhibition for Cancer Therapy
S. Saini (2008)
Angiogenesis in breast neoplasias: biological basis and clinical relevance
J. Manel (2008)
10.1586/14737159.8.3.301
Anti-VEGF therapy: the search for clinical biomarkers
R. Longo (2008)
10.2217/BMT-2019-0002
Targeting metastasis through the inhibition of interleukin 6 and 8
Hasini Jayatilaka (2019)
10.1188/09.CJON.S1.11-18
New Options for Metastatic Breast Cancer
D. Frye (2009)
10.1016/B978-1-4160-5895-3.10058-0
Management of Heart Failure Patients with Malignancy
E. T. Yeh (2011)
10.4161/cbt.7.10.6538
Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206
S. Rizvi (2008)
10.1002/jps.21286
Antiangiogenic drugs: current knowledge and new approaches to cancer therapy.
J. L. Mauriz (2008)
10.1007/s00280-011-1674-0
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine
J. Infante (2011)
10.1016/j.hfc.2011.03.004
Molecular mechanisms of hypertension and heart failure due to antiangiogenic cancer therapies.
Meredith L. Rees (2011)
10.1016/j.semradonc.2016.06.003
Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.
C. Corso (2016)
10.1016/j.clbc.2016.07.005
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
D. Yardley (2016)
10.3892/MCO.2016.800
Cardiotoxicity associated with targeted cancer therapies (Review)
Zongyou Chen (2016)
10.1007/S00108-006-1728-2
[Treatment of breast cancer: from hormones to antibodies].
J. Eucker (2006)
10.1159/000491387
Anti VEGF-TKI Treatment and New Renal Adverse Events Not Reported in Phase III Trials
L. Paschke (2018)
10.1007/s00280-018-3617-5
Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
Sakura Iizumi (2018)
10.1007/s00520-010-1069-5
Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials
O. Freedman (2010)
10.1097/HJH.0b013e32835c1d1b
Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1
S. Lankhorst (2013)
10.1016/j.bcp.2012.01.023
Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.
Manmei Li (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar